Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR recommendations help in refining the relevant place of different disease-modifying anti-rheumatic drugs (DMARDs) in treatment schedules. At present, new drugs are in phase of development, mainly Janus Kinase inhibitors (JAKis), however, specific treatment strategies seem to count more than individual DMARDs in terms of treatment responses, given the substantial lack of head-to-head comparisons between specific biological (b) and targeted synthetic (ts)DMARDs, and with the general perception of a similar efficacy profile across drugs. In this setting, when reliable biomarkers able to predict treatment responses are lacking, treatment decisions are mainly driven by specific clinical or individual factors, given the recognised role of comorbidities, treatment-specific side effects, patients’ preferences, and costs on drug choice. In this narrative review, the authors give their specific point of view on the management of RA, based on a critical revision of the literature published in 2019, focusing on relevant novelties and future research directions.

Silvagni, E., Giollo, A., Sakellariou, G., Ughi, N., D'Amico, M., Scire, C., et al. (2020). One year in review 2020: novelties in the treatment of rheumatoid arthritis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 38(2), 181-194.

One year in review 2020: novelties in the treatment of rheumatoid arthritis

Scire C. A.
Penultimo
;
2020

Abstract

Rheumatoid arthritis (RA) management is driven by evidence, and new 2019 EULAR recommendations help in refining the relevant place of different disease-modifying anti-rheumatic drugs (DMARDs) in treatment schedules. At present, new drugs are in phase of development, mainly Janus Kinase inhibitors (JAKis), however, specific treatment strategies seem to count more than individual DMARDs in terms of treatment responses, given the substantial lack of head-to-head comparisons between specific biological (b) and targeted synthetic (ts)DMARDs, and with the general perception of a similar efficacy profile across drugs. In this setting, when reliable biomarkers able to predict treatment responses are lacking, treatment decisions are mainly driven by specific clinical or individual factors, given the recognised role of comorbidities, treatment-specific side effects, patients’ preferences, and costs on drug choice. In this narrative review, the authors give their specific point of view on the management of RA, based on a critical revision of the literature published in 2019, focusing on relevant novelties and future research directions.
Articolo in rivista - Review Essay
rheumatoid arthritis; treatment;
English
181
194
14
Silvagni, E., Giollo, A., Sakellariou, G., Ughi, N., D'Amico, M., Scire, C., et al. (2020). One year in review 2020: novelties in the treatment of rheumatoid arthritis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 38(2), 181-194.
Silvagni, E; Giollo, A; Sakellariou, G; Ughi, N; D'Amico, M; Scire, C; Huizinga, T
File in questo prodotto:
File Dimensione Formato  
Silvagni et al. - 2020 - One year in review 2020 novelties in the treatmen.pdf

accesso aperto

Descrizione: articolo principale - free to view
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 374.1 kB
Formato Adobe PDF
374.1 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/355166
Citazioni
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 40
Social impact